Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises BICO in conjunction with directed share issue worth MSEK 487 to Sartorius
Mandate

Vinge advises BICO in conjunction with directed share issue worth MSEK 487 to Sartorius

December 09, 2022 Capital Markets and Public M&A Life Sciences & Health

Vinge has advised BICO Group AB in connection with a directed share issue to Sartorius AG, adding a total amount of MSEK 487 to BICO. The subscription price of SEK 76 was equivalent to a premium of 2.7 per cent compared with a 3-day VWAP. In connection with the share issue, BICO and Sartorius have entered into an extensive co-operation agreement concerning technical, sales and marketing issues.

Vinge’s team consisted of Anders Strid, Edin Agic and company registrations assistant Daniela Maniscalchi.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025